Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Nephrol Dial Transplant ; 26(4): 1388-92, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20844185

RESUMO

BACKGROUND: Sensitized patients (pts) may develop acute antibody-mediated rejection (AMR) due to preformed donor-specific antibodies, undetected by pre-transplant complement-dependent cytotoxicity (CDC) crossmatch (XM). We hypothesized that C4d staining in 1-h post-reperfusion biopsies (1-h Bx) could detect early complement activation in the renal allograft due to preformed donor-specific antibodies. METHODS: To test this hypothesis, renal transplants (n = 229) performed between June 2005 and December 2007 were entered into a prospective study of 1-h Bx and stained for C4d by immunofluorescence. Transplants were performed against a negative T-cell CDC-XM with the exception of three cases with a positive B-cell XM. RESULTS: All 229 1-h Bx stained negative for C4d. Fourteen pts (6%) developed AMR. None of the 14 protocol 1-h Bx stained positive for C4d in peritubular capillaries (PTC). However, all indication biopsies-that diagnosed AMR-performed at a median of 8 days after transplantation stained for C4d in PTC. CONCLUSIONS: These data show that C4d staining in 1-h Bx is, in general, not useful for the early detection of AMR when CDC-XM is negative.


Assuntos
Complemento C4b/imunologia , Citotoxicidade Imunológica , Rejeição de Enxerto/imunologia , Teste de Histocompatibilidade , Isoanticorpos/imunologia , Transplante de Rim/efeitos adversos , Fragmentos de Peptídeos/imunologia , Adolescente , Adulto , Biópsia , Complemento C4b/metabolismo , Feminino , Rejeição de Enxerto/etiologia , Humanos , Rim/patologia , Rim/cirurgia , Nefropatias/complicações , Nefropatias/terapia , Masculino , Pessoa de Meia-Idade , Fragmentos de Peptídeos/metabolismo , Estudos Prospectivos , Reperfusão
2.
Transplantation ; 81(6): 840-4, 2006 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-16570005

RESUMO

BACKGROUND: We reviewed our experience with third, fourth, and fifth renal transplants performed by the extraperitoneal access. METHODS: The charts of 21 third and subsequent transplants performed extraperitoneally were reviewed. Surgical aspects, the occurrence of rejection episodes, delayed graft function (DGF), graft and patient survival were evaluated and compared with 1560 first transplants in adults with nonmanipulated fossa performed in the same period. RESULTS: Transfusion was necessary in 52% of the retransplants and in 5.7% of the first transplants (P<0.0001). Mean operative time was 327 min for retransplants and 212 min for first transplants (P<0.0001). Surgical complications occurred in 4 patients (19%): two arterial thrombosis and two ureteral obstructions. DGF occurred in 11 patients (52%) among retransplants and in 453 (29%) among first transplants (P=0.028). Acute rejection occurred in 7 (33.3%) retransplants and in 530 first transplant patients (33.9%). The mean serum creatinine among retransplant patients 30 days and one year after transplantation was 2.5 mg/dl and 1.8 mg/dl. One-year graft survival was 57.1% (75% for live and 46% for cadaver donors) for retransplants and 86% for first transplant patients (P<0.0001). CONCLUSION: Third and subsequent transplants performed extraperitoneally are more time-consuming and require more transfusions in the perioperative period. A higher but acceptable incidence of arterial thrombosis and urinary obstruction were observed. One-year graft survival was better with live donor grafts, but was still lower when compared with first transplants using the same surgical technique.


Assuntos
Transplante de Rim/métodos , Adolescente , Adulto , Transfusão de Sangue , Creatinina/sangue , Feminino , Sobrevivência de Enxerto , Humanos , Transplante de Rim/mortalidade , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/etiologia
3.
Rev. med. (Säo Paulo) ; 87(3): 166-177, jul.-set. 2008. ilus, tab, graf
Artigo em Português | LILACS | ID: lil-517607

RESUMO

As doenças da próstata apresentam grande relevância clínica, pela alta frequência com que ocorrem no cotidiano e pelas consequências que ensejam. A hiperplasia benigna atinge entre 70 e 90% dos homens maduros, um terço deles apresentam manifestações clínicas mais significativas e, por isto, precisam ser tratados. Nesse sentido, os especialistas dispõem de opções medicamentosas...


Prostate diseases occur with high frequency in the clinical setting and can compromise patients'quality or extent of life. Benign prostatic hiperplasia is seen in 70-90% of men and is the cause of disturbing urinary symptoms in none third of them. In these symptomatic patients medical treatment with 5 a-redutase inhibitors or a-blockers can improve the urinary manifestations...


Assuntos
Humanos , Masculino , Doenças Prostáticas , Hiperplasia Prostática , Neoplasias da Próstata
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA